Multimodal MR Imaging (Diffusion, Perfusion, and Spectroscopy): Is It Possible to Distinguish Oligodendroglial Tumor Grade and 1p/19q Codeletion in the Pretherapeutic Diagnosis?

REFERENCES

1. 1.↵
   1. Jenkins RB,
   2. Blair H,
   3. Ballman KV,
   4. et al

   . A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852–61

   Abstract/FREE Full Text
2. 2.↵
   1. Smith JS,
   2. Perry A,
   3. Borell TJ,
   4. et al

   . Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636–45

   Abstract/FREE Full Text
3. 3.↵
   1. Walker C,
   2. Haylock B,
   3. Husband D,
   4. et al

   . Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 2006;66:1661–67

   CrossRef
4. 4.↵
   1. Sasaki H,
   2. Zlatescu MC,
   3. Betensky RA,
   4. et al

   . Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligodendroglioma”. J Neuropathol Exp Neurol 2002;61:58–63

   PubMedWeb of Science
5. 5.↵
   1. Dean BL,
   2. Drayer BP,
   3. Bird CR,
   4. et al

   . Gliomas: classification with MR imaging. Radiology 1990;174:411–15

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Law M,
   2. Yang S,
   3. Wang H,
   4. et al

   . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98

   Abstract/FREE Full Text
7. 7.↵
   1. Jenkinson MD,
   2. Smith TS,
   3. Joyce KA,
   4. et al

   . Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006;48:703–13

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Law M,
   2. Yang S,
   3. Babb JS,
   4. et al

   . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746–55

   Abstract/FREE Full Text
9. 9.↵
   1. Stadlbauer A,
   2. Gruber S,
   3. Nimsky C,
   4. et al

   . Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006;238:958–69

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Jenkinson MD,
    2. Smith TS,
    3. Brodbelt AR,
    4. et al

    . Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging 2007;26:1405–12

    CrossRefPubMed
11. 11.↵
    1. Law M,
    2. Brodsky JE,
    3. Babb J,
    4. et al

    . High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: preliminary results of molecular studies in gliomas with elevated perfusion. J Magn Reson Imaging 2007;25:1113–19

    CrossRefPubMed
12. 12.↵
    1. Jenkinson MD,
    2. du Plessis DG,
    3. Smith TS,
    4. et al

    . Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884–91

    Abstract/FREE Full Text
13. 13.↵
    1. Jenkinson MD,
    2. Smith TS,
    3. Joyce K,
    4. et al

    . MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 2005;64:2085–89

    CrossRef
14. 14.↵
    1. Kapoor GS,
    2. Gocke TA,
    3. Chawla S,
    4. et al

    . Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 2009;92:373–86

    CrossRefPubMed
15. 15.↵
    1. Louis DN,
    2. Ohgaki H,
    3. Wiestler OD,
    4. et al

    . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Metellus P,
    2. Coulibaly B,
    3. Colin C,
    4. et al

    . Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010;120:719–29

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Vanhamme L,
    2. van den Boogaart A,
    3. Van Huffel S

    . Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35–43

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Le Fur Y,
    2. Nicoli F,
    3. Guye M,
    4. et al

    . Grid-free interactive and automated data processing for MR chemical shift imaging data. MAGMA 2010;23:23–30

    CrossRefPubMed
19. 19.↵
    1. Wetzel SG,
    2. Cha S,
    3. Johnson G,
    4. et al

    . Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Breiman L

    . Random forests. Machine Learning 2001;45:5–32

    CrossRefWeb of Science
21. 21.↵
    1. Möller-Hartmann W,
    2. Herminghaus S,
    3. Krings T,
    4. et al

    . Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002;44:371–81

    CrossRefPubMedWeb of Science
22. 22.↵
    1. White ML,
    2. Zhang Y,
    3. Kirby P,
    4. et al

    . Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 2005;26:784–90

    Abstract/FREE Full Text
23. 23.↵
    1. Megyesi JF,
    2. Kachur E,
    3. Lee DH,
    4. et al

    . Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303–06

    Abstract/FREE Full Text
24. 24.↵
    1. Zlatescu MC,
    2. TehraniYazdi A,
    3. Sasaki H,
    4. et al

    . Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001;61:6713–15

    Abstract/FREE Full Text
25. 25.↵
    1. Hilario A,
    2. Ramos A,
    3. Perez-Nuñez A,
    4. et al

    . The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol 2012;33:701–07

    Abstract/FREE Full Text
26. 26.↵
    1. Whitmore RG,
    2. Krejza J,
    3. Kapoor GS,
    4. et al

    . Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 2007;107:600–09

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Spampinato MV,
    2. Smith JK,
    3. Kwock L,
    4. et al

    . Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007;188:204–12

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Xu M,
    2. See SJ,
    3. Ng WH,
    4. et al

    . Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005;56:919–26; discussion 919–26

    PubMedWeb of Science
29. 29.↵
    1. Chawla S,
    2. Wang S,
    3. Wolf RL,
    4. et al

    . Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007;28:1683–89

    Abstract/FREE Full Text
30. 30.↵
    1. Galanaud D,
    2. Nicoli F,
    3. Chinot O,
    4. et al

    . Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. Magn Reson Med 2006;55:1236–45

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Smith JK,
    2. Castillo M,
    3. Kwock L

    . MR spectroscopy of brain tumors. Magn Reson Imaging Clin N Am 2003;11:415–29, v–vi

    CrossRefPubMed
32. 32.↵
    1. Gupta RK,
    2. Cloughesy TF,
    3. Sinha U,
    4. et al

    . Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000;50:215–26

    CrossRefPubMed